Key result
Prestroke treatment with angiotensin receptor blockers was independently associated with a reduced risk of poor outcome after acute cerebral infarction (OR 0.41; 95% CI 0.23-0.78; P=0.003).
Why the study?
Does prestroke treatment with ARB reduce stroke severity and improve outcome in patients with acute cerebral infarction?
Observational (n=1,968)
Does prestroke treatment with ARB reduce stroke severity and improve outcome in patients with acute cerebral infarction?
Odds Ratio: 0.41 (95% CI 0.23–0.78)
p-value: p=0.003
Prestroke treatment with angiotensin receptor blockers is associated with reduced stroke severity and better functional outcomes at discharge in patients with acute cerebral infarction.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for prestroke ARB benefit in acute stroke; prospective trials needed before clinical adoption.
Fuentes et al. (2010) conducted an observational in acute cerebral infarction (n=1,968). Angiotensin receptor blockers (ARB) vs. No ARB treatment was evaluated on Poor outcome (OR 0.41, 95% CI 0.23-0.78, p=0.003). Prestroke treatment with angiotensin receptor blockers was independently associated with a reduced risk of poor outcome after acute cerebral infarction (OR 0.41; 95% CI 0.23-0.78; P=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: